Shares of Verizon and Amgen are retreating Wednesday morning, sending the Dow Jones Industrial Average into negative territory. The Dow was most recently trading 148 points lower (-0.4%), as shares of ...

Amgen (NASDAQ:AMGN) shares were on track for its seven straight sessions of gains on Monday, as the stock rose nearly 3% to ...

Biotechnology company, Amgen, has announced that it has entered into a definitive agreement to acquire deCODE Genetics, a global leader in human genetics, for US $415 million. The all-cash ...

US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...

THOUSAND OAKS, Calif., Feb. 14, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at Citi's 2025 Virtual Oncology Leadership Summit at 3:00 p.m. ET on Wednesday, Feb. 19, 2025. Jean-Charles ...

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen ...

Ratings for Amgen AMGN were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ...

Amgen and Ideaya Biosciences are winding down their cancer combination study, closing off one way the Big Biotech was looking to dial up the efficacy of its PRMT5 inhibitor AMG 193. The ...

About the ROCKET Phase 3 Program ROCKET is a comprehensive, global Phase 3 clinical trial program comprised of eight studies intended to establish the safety and efficacy profile of rocatinlimab in ...